Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2004-11-30
2011-11-29
Gussow, Anne M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S093100, C424S093700, C424S133100, C424S136100
Reexamination Certificate
active
08066989
ABSTRACT:
The present invention refers to a method of treating tumor growth and metastasis in a mammal, the treating comprising administering allogeneic effector cells together with trifunctional bispecific or trispecific antibodies or a combination thereof having the following properties:a) binding to a T cellb) binding to at least one antigen on a tumor cellc) binding via their Fc portion in the case of trifunctional bispecific antibodies or via third specificity in the case of trispecific antibodies to Fc receptor positive cells;the antibodies redirecting the allogenic cells away from host tissues in order to substantially reduce or avoid a graft versus host disease.
REFERENCES:
patent: 5985276 (1999-11-01), Lindhofer et al.
patent: 6210668 (2001-04-01), Lindhofer et al.
patent: 6551592 (2003-04-01), Lindhofer et al.
patent: 6994853 (2006-02-01), Lindhofer et al.
patent: 7018632 (2006-03-01), Lindhofer et al.
patent: 2002/0009430 (2002-01-01), Lindhofer et al.
patent: 2002/0051780 (2002-05-01), Lindhofer
patent: 2003/0223999 (2003-12-01), Lindhofer
patent: 2005/0255110 (2005-11-01), Lindhofer et al.
patent: 0885614 (1998-12-01), None
patent: WO03/015705 (2003-02-01), None
Ezzell, C. Cancer “Vaccines”: an idea whose time has come? Journal of NIH Research, 1995. vol. 7, pp. 46-49.
Forni, G., Lollini, P.L., Musiani, P., and Colombo, M.P. Immunoprevention of cancer: is the time ripe? Cancer Research, 2000. vol. 60, pp. 2571-2575.
Ruf, P. and Lindhofer, H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood, 2001. vol. 98 No. 8, pp. 2526-2534.
Slavin, S., Morecki, S., Weiss, L., and Or, R. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. 2003. Critical Reviews in Oncology/Hematology. vol. 46, pp. 139-163.
Kroesen, Haar, Spakman, Willemse, Sleijfer, De Vries, Mulder, Berendsen, Limburg, The, and De Leij. Local antitumor treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunology and Immunotherapy, 1993. vol. 37, pp. 400-407.
European Search Report for corresponding European patent application No. 04028473.9 dated Jun. 28, 2005.
Simoes et al. “Bi20 a new trifunctional bispecific antibody (CD20XCD3) in the treatment of restraint B cell tumors: First Clinical data.”Blood, 102 (11): p. 297b, Nov. 16, 2003. Abstract.
Simoes et al. “T cell response against CD20+ tumor cell lines and B-CLL cells induced by a new trifunctional bispecific antibody Bi20 (CD20XCD3)”,Blood, 102 (11): p. 297b, Nov. 16, 2003. Abstract.
Sen et al. “Use of Anti-CD3 * Anti-HER2
eu Bispecific Antibody for Redirecting Cytotoxicity of Activated T Cells Toward HER2
eu+ Tumors”,Journal of Hematotherapy&Stem Cell Research, 10: 247-260, 2001.
Slavin, Shimon, “Immunotherapy of Cancer with Alloreactive Lymphocytes”The Lancet Oncology, 2: pp. 491-498, 2001.
Childs et al., “Regression of Metastatic Reenal-Cell Carcinoma After Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation”Massachusetts Medical Society, 343 (11): 754-758, Sep. 14, 2000.
European Search Report for corresponding European patent application No. 04028473.9 dated Sep. 29, 2005.
Schmitt et al., “Opsonization with a trifunctional bispecific (αCD3×αEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes”,International Journal of Oncology, 25(4): pp. 841-848, Oct. 2004.
Fowler et al., “Clinical “Cytokine Storm” as Revealed by Monocyte Intracellular Flow Cytometry: Correlation of Tumor Necrosis Factor α With Severe Gut Graft-Versus-Host Disease”,Clinical Gastroenterology and Hepatology, 2(3): pp. 237-245, Mar. 2004.
Zeidler et al., “The FC-Region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells”,British Journal of Cancer, 83(2): pp. 261-266, Jul. 2000.
Crespo et al., “Immunophenotypic and Functional Characterizations of Cord Blood Dendritic Cells”,Stem Cells and Development, 13(1): pp. 63-70, Feb. 2004.
Verdonck et al., “Graft-versus-myeloma effect in two cases”,The Lancet, 347(9004): pp. 800-801, 1996.
Simoes et al., “T Cell Response Against B Cell Tumor Lines Induced by Bi20, a Novel Trifunctional Bispecific (CD20×CD3) Anitbody”,Blood, W.B. Saunders Company, 100(11): Abstract No. 4789, Nov. 16, 2002.
Lindhofer et al. Bispecific antibodies effectively purge cancer cells from peripheral blood stem cells collections without affecting colony forming units. Experimental Hematology, vol. 25, (1997), pp. 879.
Communication Pursuant to Article 94(3) EPC corresponding to European Application No. 04 028 473.9-2401 dated Jul. 2, 2009.
Harris, D., “In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood,” Bone Marrow Transplantation, vol. 15, pp. 17-23 (1995).
Haagen et al., “Interaction of human monocyte Fc gamma receptors with rat IgG2b,” J. Immunology, vol. 154, pp. 1852-1860 (1995).
Lindhofer et al., “Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies,” J. Immunol., vol. 155, pp. 219-225 (1995).
Mocikat et al., “A Mouse Model for the Preclinical Evaluation of Immunosuppressive Effector Functions of Human Isotypes: The Human IgG1 Isotype is Superior to IgG3,” Transplantation 57 (1994), 405.
Abramowicz et al., “Release of Tumor Necrosis Factor, Interleukin-2, and Gamma-Interferon in Serum After Injection of OKT3 Monoclonal Antibody in Kidney Transplant Recipients,” Transplantation, vol. 47, No. 4, pp. 606-608 (Apr. 1989).
Baeuerle et al., “Bispecific antibodies for polyclonal T-cell engagement,” Curr. Opin. Mol. Ther., vol. 5, No. 4, pp. 413-419 (2003).
Canevari et al., “Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody,” J. Natl. Cancer Inst., vol. 87, pp. 1463-1469 (1995).
Cohen et al., “Spontaneous and IL-2 induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens,” J. Immunol., vol. 151, pp. 4803-4810 (1993).
De Gast et al., “CD8 T cell activation after intravenous administration of CD3×CD19 bispecific antibody in patients with non-Hodgkin lymphomas,” Cancer Immunol. Immunother., vol. 40, pp. 390-396 (1995).
Dreier et al., “Extremely potent, rapid and costimulation-independent cytotoxic T cell response against lymphoma cells catalayzd by a single-chain bispeicifc antibody,” Int. J. Cancer, vol. 100, pp. 690-697 (2002).
Friedrich et al., “Antibody-directed effector cell therapy of tumors: analysis and optimization using a physiologically based pharmacokinetic model,” Neoplasia, vol. 4, No. 5, pp. 449-463 2002).
Gratwohl, “Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia,” Blood, vol. 100, No. 12, pp. 3877-3886 (Dec. 1, 2002).
Kolb et al., “Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia,” Blood, vol. 86, pp. 2041-2050 (1995).
Kolb et al., “Graft-versus-leukemia reactions in allogeneic chimeras,” Blood, vol. 103, No. 3, pp. 767-776 (Feb. 1, 2004).
Kudo et al., “Specific targeting immunotherapy of cancer with bispecific antibodies,” Tohoku J. Exp. Med., vol. 188, No. 4, pp. 275-288 (1999).
Lindhofer et al., “Bispecific antibodies effectively purge cancer cells from peripheral blood stem cells collections without affecting colony forming units,” Experimental Hematology, vol. 25, pp. 879 (1997).
Lindhofer Horst
Morecki Shoshana
Slavin Shimon
Gussow Anne M.
Jenkins Wilson Taylor & Hunt, P.A.
Trion Pharma GmbH
LandOfFree
Method of treating tumor growth and metastasis by using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating tumor growth and metastasis by using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating tumor growth and metastasis by using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298002